All In Biotech

Drug Trial Radar · NCT07229716

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Apr 4, 2026

Primary completion

Jun 18, 2026

Study completion Jun 18, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.

Conditions

  • Pulmonary Fibrosis

Interventions

  • HRS-9813 CapsuleDrug

    HRS-9813 capsule, specified dose on specified days.

  • Nintedanib Soft CapsulesDrug

    Nintedanib soft capsules, specified dose on specified days.

  • Pirfenidone TabletsDrug

    Pirfenidone tablets, specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The maximum plasma concentration (Cmax)Time frame: From Day 1 to Day 24.
  2. Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf)Time frame: From Day 1 to Day 24.
  3. Area under the concentration curve from time 0 to time of last quantifiable concentration (AUC0-tau)Time frame: From Day 1 to Day 24.
  4. Area under the concentration curve from time 0 to time t (AUC0-t)Time frame: From Day 1 to Day 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tangdu Hospital, Fourth Military Medical University

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.